Candesartan

Candesartan Impurities

Candesartan impurities include process-related compounds, degradation products, and structurally related analogs formed during synthesis or storage. These impurities are monitored to ensure the safety and efficacy of this angiotensin II receptor blocker used in hypertension and heart failure. All materials are structurally confirmed and qualified under ICH guidelines for pharmaceutical analysis and toxicological evaluation.

Candesartan EP Impurities

We offer a full suite of Candesartan impurities that comply with European Pharmacopoeia (EP) standards. These are essential for method development, impurity profiling, and stability testing. Analytical techniques such as HPLC, LC-MS, and NMR are used for their identification and quantification.

Candesartan Related Compounds

Our catalog includes Candesartan-related substances such as synthetic intermediates, stereoisomers, and stable isotope-labeled analogs. These compounds are vital for forced degradation studies, impurity identification, and genotoxicity screening. All materials are rigorously characterized and supported by detailed analytical documentation.

Candesartan Impurity Reference Standards

Candesartan impurity reference standards are supplied with validated analytical data including NMR, MS, and HPLC purity. These standards are used in pharmaceutical R&D, ANDA and DMF filings, method validation, and GMP-compliant quality control. EP/USP traceable materials are available upon request, and all products meet international regulatory expectations.